Inactive Instrument

Akcea Therapeutics, Inc.

AKCA

US00972L1070

AKCEA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 29, 2020 at 03:24 am IST

Item 8.01. Other Events.

On January 28, 2020, Akcea Therapeutics, Inc. (the "Company") announced positive topline results from the Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease. A copy of the press release is attached to this Report as Exhibit 99.1 and is incorporated by reference into this Item 8.01.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



 Exhibit No.   Description

 99.1            Press Release, dated January 28, 2020, issued by the Company

--------------------------------------------------------------------------------

Latest news about Akcea Therapeutics, Inc.

Aspen Neuroscience, Inc. Appoints Lisa Johnson-Pratt as Senior Vice President, Therapeutic Program Lead	14/02	CI
Mersana Therapeutics, Inc. Announces Carla Poulson as Chief Human Resources Officer	19/21/19	CI
Akcea Therapeutics Announces Scottish Medicines Consortium Enabled Access to Volanesorsen on the National Health Service in Scotland for the Treatment of Familial Chylomicronaemia Syndrome	09/20/09	CI
Akcea Therapeutics, Inc. Announces Management Changes	13/20/13	CI
Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P TMI Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGS:AKCA) dropped from S&P Global BMI Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Comp Value Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Value Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Value-Dynamic Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Growth-Dynamic Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Value-Dynamic Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Comp Growth Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Growth Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell Small Cap Completeness Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 3000 Growth Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Growth Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2500 Dynamic Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Growth-Dynamic Index	12/20/12	CI
Akcea Therapeutics, Inc.(NasdaqGM:AKCA) dropped from Russell 2000 Dynamic Index	12/20/12	CI
Ionis Pharmaceuticals, Inc. completed the acquisition of 24.23% stake in Akcea Therapeutics, Inc..	12/20/12	CI

Chart Akcea Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+51.63%	796B
NOVO NORDISK A/S	+40.84%	628B
JOHNSON & JOHNSON	-5.10%	358B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+9.95%	301B
ASTRAZENECA PLC	+17.55%	244B
ROCHE HOLDING AG	+4.01%	228B
NOVARTIS AG	+12.76%	214B
AMGEN INC.	+6.99%	165B

Other Pharmaceuticals